[Zidovudine in prevention of HIV transmission by the infected mother to her child].
The effectiveness of a zidovudine prophylaxis to decrease vertical HIV transmission was tested in a multi-centre (59 clinics in the USA and France), randomised, placebo-controlled study. The mother was given zidovudine orally from the 14th gestational week and intravenously during delivery. The child was treated orally for the first 6 weeks of life. This prophylactic treatment resulted in a significant reduction of vertical HIV transmission from 26 to 8%. Although there are still some open questions, especially concerning the long-term consequences for the child, the Swiss Associations of Gynaecology and Obstetrics and of Paediatrics recommend using zidovudine for prophylaxis in the routine care of HIV-infected pregnant women.
D000284:Administration, Oral; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005602:France; D015658:HIV Infections / Q000401:mortality / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D007262:Infusions, Intravenous; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D014481:United States; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use*
D015215:Zidovudine
Zidovudin zur Prophylaxe der HIV-Ubertragung von der infizierten Mutter auf ihr Kind.